In B-ALL several PI3K/AKT pathway inhibitors have been designed and evaluated both preclinically and clinically with most studies focusing on PI3K and mTOR complexes [10]. The gene discussed is AKT1; the disease is precursor B-cell acute lymphoblastic leukemia.